Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
Holding ABSI?
Track your performance easily
Earnings Data
Report Date
Mar 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.22Last Year’s EPS
-$0.25Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -30.14%
|Next Earnings Date:Mar 19, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, such as collaborations with AstraZeneca and Twist Bioscience, financial stability, and upcoming strategic events. However, it also noted increased R&D expenses, a delay in the ABS-301 program, and modest revenue figures. The positive elements slightly outweigh the negative aspects.Company Guidance
During the Absci Q3 2024 earnings call, guidance was provided on multiple key metrics and strategic directions. The company reported a revenue of $1.7 million for the quarter, with research and development expenses increasing to $18 million, primarily due to IND-enabling studies for ABS-101. Selling, general, and administrative expenses slightly decreased to $9.3 million. Absci concluded the quarter with $127.1 million in cash and short-term investments, projecting a cash usage of approximately $75 million for the year, which is lower than previously expected. They anticipate initiating Phase I clinical studies for ABS-101 in the first half of 2025, with interim data expected in the latter half. Additionally, they plan to complete mode of action validation studies for ABS-301 within the first half of 2025. Absci is also pursuing further partnerships, expecting to sign with two more partners before the end of the year, following recent collaborations with Twist Bioscience and others. Their financial planning indicates that current resources will fund operations into the first half of 2027.Successful Collaboration with AstraZeneca
Achieved the first milestone in collaboration with AstraZeneca by delivering AI de novo antibody sequences in just 6 months.
New Partnership with Twist Bioscience
Announced a partnership with Twist Bioscience to design a novel antibody using generative AI, combining Absci's and Twist's platforms.
Upcoming R&D Day
Planned R&D Day on December 12, 2024, to unveil new asset programs and share updates on existing programs.
Financial Stability and Reduced Cash Burn
Ended Q3 with $127.1 million in cash and reduced cash burn estimate for 2024 from $80 million to $75 million.
---
ABSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $4.28 | $3.64 | -14.95% |
| Aug 14, 2024 | $3.73 | $4.14 | +10.99% |
| May 14, 2024 | $5.06 | $4.83 | -4.55% |
| Mar 21, 2024 | $5.09 | $5.28 | +3.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AbSci (ABSI) report earnings?
AbSci (ABSI) is schdueled to report earning on Mar 19, 2025, TBA Not Confirmed.
What is AbSci (ABSI) earnings time?
AbSci (ABSI) earnings time is at Mar 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABSI EPS forecast?
ABSI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.22.
---